Status: Not yet recruiting
Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema
Phase I, prospective, interventional, open-label, multicenter clinical trial to evaluate the safety of intravitreal PRO-169 through the presence of serum anti-drug antibodies (ADAs) to bevacizumab.
Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Laboratorios Sophia S.A de C.V.Updated: Mar 13, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years. [+9]
Chronic kidney disease with renal failure (glomerular filtration rate [eGFR] <15... [+30]